Commercialization of an Improved Treatment of Extremity Fractures Using a Regenerative Bone Adhesive to Accelerate Bone Healing in Aging Patients
使用再生骨粘合剂加速老年患者骨愈合的四肢骨折改进治疗方法的商业化
基本信息
- 批准号:10822079
- 负责人:
- 金额:$ 174.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-30 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAddressAdhesivesAdverse eventAgeAgingAnesthesia proceduresAnimalsAwardBiologicalCadaverCarpal Tunnel SyndromeClinical InvestigatorClinical ResearchClinical TrialsComplex Regional Pain SyndromesComplicationDefectDevelopmentDistalElderlyElectroplatingEnrollmentEquationEventFailureFatigueFillerFormulationFractureFracture FixationFundingGoalsGood Clinical PracticeGrantGuidelinesHumanIncidenceInfectionInjuryInstitutionInterventionLifeLimb structureLower ExtremityMarket ResearchMetalsMethodsMissionModelingMulti-Institutional Clinical TrialNational Institute on AgingOperative Surgical ProceduresOrthopedicsOryctolagus cuniculusOutcome StudyPatientsPerformancePeriodicityPersonsPhasePopulationProcessQuality of lifeRadius FracturesRecurrenceRegional AnatomyReportingResearchRiskRuptureSafetySamplingSecond Look SurgerySheepSiteSmall Business Innovation Research GrantSpecific qualifier valueSterilitySterilizationSurgeonSyndromeSystemTechniquesTendon structureTestingTrainingTraumaUpper ExtremityValidationWorkbiomaterial compatibilitybonebone fracture repairbone healingclinical research sitecommercializationcostdesign verificationexperiencefallsfirst-in-humanfragility fracturehealingimage guidedimplant designimprovedirritationmortalitynovelpatient populationpre-clinical researchpreclinical developmentpreclinical studypreventprimary endpointproduct developmentprogramsradiological imagingregenerativesafety studysample fixationstandard of carestanding heightusabilityvalidation studies
项目摘要
Project Abstract/Summary
In the U.S., about 2.1 million people experience a fragility fracture each year. This number is expected to double
or triple by 2040 as the population ages. Injuries in the upper and lower extremities equate to more than 40% of
fragility fractures, and experiencing a prior fracture is associated with an 86% increased risk of recurrence. Falls
from standing height and other low-energy trauma account for 87% of all orthopedic fractures among the elderly.
External fixation, percutaneous pinning, and open reduction internal fixation with locking plates are interventions
that are currently being used to treat extremity fractures. Despite advances in surgical technique and implant
design, nonunion, malunion, and hardware failure continue to remain a significant cause of revision surgery in
the elderly. Complication rates as high as 36% have been reported and involve onset of carpal tunnel syndrome,
complex regional pain syndrome, tendon irritation and rupture, and deep infection.
To address this problem, RevBio developed Tetranite® (TN), a novel bone adhesive that can fill gaps in bone,
fixate bone fragments, and accelerate healing through its osteoconductive effects. TN can be used as an adjunct
to traditional hardware fixation to provide immediate load sharing between the metal plate and screw systems,
and bone. It provides additional stability by enhancing fracture stabilization to achieve better healing and
prevents hardware failure. It can also be injected percutaneously a standalone method of fixation providing an
option to surgically treat fractures without the need for open reduction, metal hardware, or anesthesia.
Proposed work to treat extremity fractures in the elderly will bridge off existing late-stage development of TN
supported by a SBIR Phase II award from the National Institutes of Aging entitled, “Improved Treatment of Distal
Radius Fractures Using an Image-Guided, Percutaneous Delivery of a Novel Bone Adhesive” (R44 AG060881-
02). This grant enabled formulation optimization and conduction of user validation studies with surgeons (Aim 1)
and a pivotal animal study in sheep (Aim 2) to demonstrate safety and efficacy of TN. This project is focused on
a specific indication to treat distal radius fractures; however, based on discussions with FDA and surgeons, the
impact and value of the material could be expanded to a wider set of indications across all metaphyseal fractures
in the upper and lower extremities for this same patient population. Therefore, this grant would provide additional
funding to conduct market research and supplemental pre-clinical development costs to expand its use to these
additional anatomic regions. This funding would also enable completion of biocompatibility, sterilization,
packaging, and shelf-life validations to finish late-stage development, enabling RevBio to file an IDE, and execute
a clinical study with TN as an adjunct to hardware. The overarching goal of this program is to build off successful
Phase II research and to execute Aim 1 and Aim 2 to lead to product regulatory approval for commercialization.
Long term, RevBio’s mission is to commercialize TN in order to provide surgeons with a novel product that will
enhance fixation, accelerate healing, and reduce complications associated with extremity fractures in the elderly.
项目摘要/总结
在美国,每年约有 210 万人遭受脆性骨折。这个数字预计将增加一倍
或随着人口老龄化,到 2040 年将增加两倍。上肢和下肢损伤相当于40%以上
脆性骨折,并且先前经历过骨折与复发风险增加 86% 相关。瀑布
站立高度和其他低能量创伤造成的老年人骨科骨折占 87%。
干预措施有外固定、经皮钉扎和切开复位锁定钢板内固定
目前用于治疗四肢骨折。尽管手术技术和植入物不断进步
设计、骨不连、畸形愈合和硬件故障仍然是修复手术的重要原因
老年人。据报道,并发症发生率高达 36%,其中包括腕管综合征,
复杂的局部疼痛综合征、肌腱刺激和断裂以及深部感染。
为了解决这个问题,RevBio 开发了 Tetranite® (TN),一种新型骨粘合剂,可以填充骨间隙,
固定骨头碎片,并通过其骨传导作用加速愈合。 TN可作为辅助剂
与传统的硬件固定相比,可在金属板和螺钉系统之间提供直接的负载共享,
和骨头。它通过增强骨折稳定性来提供额外的稳定性,以实现更好的愈合和
防止硬件故障。它也可以经皮注射作为一种独立的固定方法,提供
无需切开复位、金属硬件或麻醉即可进行手术治疗骨折的选择。
治疗老年人四肢骨折的拟议工作将弥补 TN 现有的后期发展
获得美国国家老龄化研究所颁发的 SBIR 第二阶段奖项的支持,该奖项名为“改善远端远端治疗”
使用图像引导、经皮输送新型骨粘合剂治疗桡骨骨折”(R44 AG060881-
02)。这笔赠款使外科医生能够优化配方并进行用户验证研究(目标 1)
以及一项针对绵羊的关键动物研究(目标 2),以证明 TN 的安全性和有效性。该项目重点关注
治疗桡骨远端骨折的具体适应症;然而,根据与 FDA 和外科医生的讨论,
该材料的影响和价值可以扩展到所有干骺端骨折的更广泛的适应症
对于同一患者群体的上肢和下肢。因此,这笔赠款将提供额外的
进行市场研究的资金和补充临床前开发成本,以将其用途扩大到这些领域
额外的解剖区域。这笔资金还将能够完成生物相容性、灭菌、
包装和保质期验证以完成后期开发,使 RevBio 能够归档 IDE 并执行
一项以 TN 作为硬件辅助的临床研究。该计划的总体目标是建立成功的
第二阶段研究并执行目标 1 和目标 2,以获得产品商业化的监管批准。
从长远来看,RevBio 的使命是将 TN 商业化,以便为外科医生提供一种新颖的产品,
加强固定,加速愈合,减少老年人四肢骨折的并发症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brian Hess其他文献
Brian Hess的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brian Hess', 18)}}的其他基金
Improved Treatment of Vertebral Compression Fractures for Elderly Patients Using an Image-Guided, Percutaneous Delivery of a Novel Bone Adhesive
使用图像引导、经皮输送新型骨粘合剂改善老年患者椎体压缩性骨折的治疗
- 批准号:
10547209 - 财政年份:2022
- 资助金额:
$ 174.67万 - 项目类别:
A Novel Bioresorbable Bone Adhesive Used to Fixate Cranial Flaps and Reduce Infection Rates
一种新型生物可吸收骨粘合剂,用于固定颅骨瓣并降低感染率
- 批准号:
10010631 - 财政年份:2020
- 资助金额:
$ 174.67万 - 项目类别:
Improved Treatment of Distal Radius Fractures Using an Image-Guided, Percutaneous Delivery of a Novel Bone Adhesive
使用图像引导、经皮输送新型骨粘合剂改善桡骨远端骨折的治疗
- 批准号:
10380629 - 财政年份:2018
- 资助金额:
$ 174.67万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 174.67万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 174.67万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 174.67万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 174.67万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 174.67万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 174.67万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 174.67万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 174.67万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 174.67万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 174.67万 - 项目类别:
Research Grant